WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?

Treatment with androgen deprivation (ADT) has for many years been a standard treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, several phase 3 randomized trials have completely changed the therapeutic approach for these patients. First, two phase 3 trials, CH...

Descripción completa

Detalles Bibliográficos
Autor principal: Omrčen, Tomislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sestre Milosrdnice University Hospital and Institute of Clinical Medical Research, Vinogradska cesta c. 29 Zagreb 2019
Materias:
Professional Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693561/
https://www.ncbi.nlm.nih.gov/pubmed/34975201
http://dx.doi.org/10.20471/acc.2019.58.s2.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693561/
https://www.ncbi.nlm.nih.gov/pubmed/34975201
http://dx.doi.org/10.20471/acc.2019.58.s2.11

Ejemplares similares